OMV discusses decarbonization strategies amid climate goals

Alfred Stern Chairman of the Executive Board of OMV OMV
Alfred Stern Chairman of the Executive Board of OMV - OMV
0Comments

Meeting the Paris Agreement’s goal of limiting global warming to 1.5°C is crucial for preventing severe climate change impacts, according to Angelika Zartl-Klik, Senior Vice President for Low Carbon Business at OMV. The path to net-zero emissions by 2050 involves significant transformations across various sectors, including energy and construction.

Current national plans aim for a modest reduction in greenhouse gas emissions by 2030, falling short of the necessary decrease to meet the agreement’s target. Hard-to-abate sectors like chemical manufacturing and construction pose significant challenges due to their carbon-intensive processes.

Jan Theulen from Heidelberg Materials highlights that concrete production significantly contributes to global emissions but offers potential decarbonization paths through efficiencies and less-polluting fuels. He emphasizes that cost increases in sustainable materials should not make building unaffordable.

Innovative solutions are being explored, such as using alternative inputs or new processes for cement production. However, scaling these solutions remains challenging. Martin Frings from OGE stresses the importance of carbon capture and storage (CCS) alongside carbon dioxide removal (CDR) technologies as essential tools for achieving climate neutrality.

CCS involves capturing CO₂ from industrial sources and storing it underground permanently. This technology could be crucial in balancing emissions from industries that cannot fully decarbonize by 2050. Theulen acknowledges CCS as a vital component in reducing clinker usage and making cement more sustainable.

OMV is committed to providing CCS solutions specifically for hard-to-abate industries, recognizing its potential in reducing carbon emissions effectively.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.